Septerna, Inc.
Septerna is a U.S.-based biotechnology company focused on discovering and developing small-molecule medicines for diseases driven by G protein-coupled receptors (GPCRs). The company operates from South San Francisco, California and advances its programs through internal research, preclinical development, and collaboration arrangements with larger pharmaceutical partners.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaInternal platform used to identify and optimize small-molecule GPCR drug candidates.
Company-owned therapeutic programs advancing through discovery, IND-enabling work, and clinical preparation.
Fee-based research services performed for pharmaceutical partners under collaboration agreements.
Potential future payments tied to development, regulatory, commercial, and sales outcomes.
Asiakkaat
Septerna’s direct customers today are pharmaceutical collaborators that fund research services and may support future development programs. Its eventual end customers, if products are approved, would be patients and healthcare providers in the therapeutic areas targeted by its GPCR programs. The company’s business model therefore spans partner-funded discovery work now and potential commercial drug sales later.
Buy research services and provide funding, milestones, and future commercialization support for partnered programs.
Patients, physicians, and payors that would use or reimburse approved therapies from Septerna's pipeline.
External partners that may access Septerna's discovery capabilities, data, or program-specific expertise.
Strategia
Septerna’s strategy is to build a differentiated GPCR drug discovery engine and convert that platform into partnered and wholly owned therapeutic programs. Near term, the company relies on collaboration revenue and external funding to support research, preclinical development, and clinical preparation. Longer term, it aims to create value through clinical advancement, regulatory approvals, and milestone and royalty economics.
Clinical and preclinical progress is the main driver of long-term value creation.
Partner agreements provide non-dilutive support and external validation of the platform.
Patent and exclusivity protection are essential for future commercialization and royalty value.
Maantiede
Septerna is headquartered in South San Francisco, California and operates as a U.S.-based biotechnology company. Its current revenue is tied to collaboration and research activities, while future product sales, if any, would likely be global and country-by-country through partner commercialization. The company also relies on third-party manufacturers and service providers, which can create cross-border supply and regulatory exposure.
Riskit
Septerna faces the typical risks of an early-stage biotech company: clinical failure, regulatory delays, and dependence on third parties for manufacturing and testing. It also has exposure to collaboration concentration, reimbursement and commercialization uncertainty, and geopolitical or trade restrictions that could affect suppliers and contract organizations. Because it has no approved products, its future value depends heavily on successful development and partner execution.
- Failure of product candidates in developmentVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company has no approved products, so pipeline setbacks would directly reduce future value.
Kohdistuu - Reliance on third-party manufacturers and research providersVaikutus: KorkeaTodennäköisyys: Kohtalainen
Septerna depends on external CROs, CMOs, and suppliers for development and testing.
Kohdistuu - Regulatory and reimbursement uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen
Commercial success depends on obtaining approvals and later payer acceptance.
Kohdistuu: Future marketed GPCR therapies
- Collaboration concentrationVaikutus: KorkeaTodennäköisyys: Matala
A meaningful share of current revenue comes from a small number of partners.
Kohdistuu - Geopolitical and trade restrictionsVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Restrictions involving China or cross-border biotech supply chains could hinder development.
Kohdistuu: Third-party service providers and materials
Kirjanpito
Harkinnanvaraiset erätRevenue is recognized as research services are performed, so timing of work drives reported revenue.
Vaikutus: Can create uneven quarterly revenue and earnings
Large collaboration payments may be recognized over time or upon achievement of obligations.
Vaikutus: Affects revenue timing and comparability across periods
A significant employee base is compensated partly with equity awards.
Vaikutus: Impacts operating expenses and dilution
Most development costs are expensed as incurred in pre-commercial biotech models.
Vaikutus: Drives reported losses and affects comparability
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Natera, Inc.
NTRA · Services-Medical Laboratories
Xencor Inc
XNCR · Pharmaceutical Preparations
Kymera Therapeutics, Inc.
KYMR · Biological Products, (No Diagnostic Substances)
Aptera Motors Corp
SEV · Motor Vehicles & Passenger Car Bodies
Aptera Motors Corp is a U.S.-based electric vehicle company focused on developing an ultra-efficient, three-wheeled solar electric vehicle.
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Filana Therapeutics, Inc
FLNA · Pharmaceutical Preparations
Päivitetty: 24.9.2026